Companies focus on hard science, long-term pay-off at stem cell meeting
This article was originally published in Scrip
Executive Summary
Just because the science is hard that doesn't mean that biotechnology firms won't conduct pioneering regenerative medicine research or that major pharmaceutical companies won't invest in cell therapies. Regulatory approval for new products and health care payer reimbursement for innovative treatments also are possible despite the novelty of the field.
You may also be interested in...
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.
Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients
Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.